Abstract

Evaluation of the investigational vaccines in this project are part of the VRC mission related to biodefense and emerging pathogens. The ongoing screening protocol, VRC 300, is designed to recruit and screen healthy, HIV-negative subjects for investigational studies of vaccines to prevent infectious diseases (other than HIV). In FY 10, this project included ongoing assessment in clinical trials of investigational vaccines against five infectious diseases: Marburg virus, Ebola virus, avian influenza, seasonal influenza and pandemic H1N1 influenza viruses. Further evaluation of influenza vaccine approaches will continue as teh VRC develops additional candidate vaccine regimens. Published results from Phase I dose clinical trials have included: an Ebola DNA vaccine study (VRC 204) Clin Vaccine Immunol, 2006. 13(11):1267-77; a West Nile virus DNA vaccine study (VRC 302) J Infect Dis, 2007. 196(12):1732-40, a SARS DNA vaccine study (VRC 301) Vaccine 2008 Nov 25;26(50):6338-43.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAAI005047-08
Application #
8148435
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2010
Total Cost
$4,251,944
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Yassine, Hadi M; McTamney, Patrick M; Boyington, Jeffery C et al. (2018) Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera. Sci Rep 8:8628
Gaudinski, Martin R; Houser, Katherine V; Morabito, Kaitlyn M et al. (2018) Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 391:552-562
Goo, Leslie; DeMaso, Christina R; Pelc, Rebecca S et al. (2018) The Zika virus envelope protein glycan loop regulates virion antigenicity. Virology 515:191-202
Grifoni, Alba; Pham, John; Sidney, John et al. (2017) Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans. J Virol :
Ishizuka, Andrew S; Lyke, Kirsten E; DeZure, Adam et al. (2016) Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22:614-23
Dowd, Kimberly A; DeMaso, Christina R; Pelc, Rebecca S et al. (2016) Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell Rep 16:1485-1491
Misasi, John; Gilman, Morgan S A; Kanekiyo, Masaru et al. (2016) Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351:1343-6
Corti, Davide; Misasi, John; Mulangu, Sabue et al. (2016) Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351:1339-42
Ewer, Katie; Rampling, Tommy; Venkatraman, Navin et al. (2016) A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med 374:1635-46
Crank, Michelle C; Gordon, Ingelise J; Yamshchikov, Galina V et al. (2015) Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS One 10:e0123969

Showing the most recent 10 out of 40 publications